The impact of vaccines and vaccinations: Challenges and opportunities for modelers

Mathematical Biosciences and Engineering

Volumn 8, Issue 1, 2011, Pages 77-93

  Curtiss III, Roy ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Immunity; Vaccination; Vaccine design; Vaccines

Indexed keywords

IMMUNOLOGICAL ADJUVANT; VACCINE;

ANIMAL; ARTICLE; COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY; INFECTION CONTROL; INNATE IMMUNITY; PANDEMIC;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, INNATE; PANDEMICS; VACCINES;

ANIMALIA;

EID: 78651366682     PISSN: 15471063     EISSN: 15510018     Source Type: Journal    
DOI: 10.3934/mbe.2011.8.77     Document Type: Article

References (197)

1. S. Akira, S. Uematsu and O. Takeuchi, Pathogen recognition and innate immunity, Cell, 124 (2006), 783-801.
2. P. Ansstasiou-Fotaki, E. Deligeoroglou and G. Kreatsas, The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece), Akush Ginekol (Sofiia), 46 (2007), 17-20.
3. G. J. Atkins, M. N. Fleeton and B. J. Sheahan, Therapeutic and prophylactic applications of alphavirus vectors, Expert Rev. Mol. Med., 10 (2008), e33.
4. O. T. Avery and W. F. Goebel, Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens, J. Exp. Med., 50 (1929), 533-550.
5. R. Barrett, C. W. Kuzawa, T. McDade and G. J. Armelagos, Emerging and re-emerging infectious diseases: The third epidemiologic transition, Annu. Rev. Anthropol., 27 (1998), 247-271.
6. C. Barrios, P. Brawand, M. Berney, C. Brandt, P. H. Lambert and C. A. Siegrist, Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: Predominance of a Th2-biased pattern which persists after adult boosting, Eur. J. Immunol., 26 (1996), 1489-1496.
7. J. M. Barry, "The Great Influenza: The Story of the Deadliest Pandemic in History," revised ed. Penguin Books, New York, 2004.
8. J. G. Bartlett, Planning for avian Influenza, Ann. Intern. Med., 145 (2006), 141-144.
9. G. M. Beards and D. W. Brown, The antigenic diversity of rotaviruses: Significance to epidemiology and vaccine strategies, Eur. J. Epidemiol., 4 (1988), 1-11.
10. A. S. Beare and R. G. Webster, Replication of avian influenza viruses in humans, Arch. Virol., 119 (1991), 37-42.
11. M. Beauregard and M. A. Hefford, Enhancement of essential amino acid contents in crops by genetic engineering and protein design, Plant Biotechnol. J., 4 (2006), 561-574.
12. M. W. Beijerinck, A Contagium vivum fluidum as the cause of the mosaic disease of tobacco leaves, Centralblatt fur Bacteriologie und Parasitenkunde, Part II, 5 (1899), 27-33.
13. E. A. Belongia, S. A. Irving, S. C. Waring, L. A. Coleman, J. K. Meece, M. Vandermause, S. Lindstrom, D. Kempf and D. K. Shay, Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1) and 2007-2008 (H3N2) infections, JAMA, 304 (2010), 1091-1098.
14. R. B. Belshe, Current status of live attenuated influenza virus vaccine in the US, Virus Res., 103 (2004), 177-185.
15. R. B. Belshe, P. M. Mendelman, J. Treanor, J. King, W. C. Gruber, P. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, D. Iacuzio and M. Wolff, The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children, N. Engl. J. Med., 338 (1998), 1405-1412.
16. R. B. Belshe, K. L. Nichol, S. B. Black, H. Shinefield, J. Cordova, R. Walker, C. Hessel, I. Cho and P. M. Mendelman, Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years, Clin. Infect Dis., 39 (2004), 920-927.
17. D. R. Bentley and G. G. Brownlee, Sequence of the N2 neuraminidase from influenza virus A/NT/60/68, Nucleic Acids Res., 10 (1982), 5033-5042.
18. O. G. Berlin, S. M. Novak, R. K. Porschen, E. G. Long, G. N. Stelma and F. W. Schaeffer, Recovery of Cyclospora organisms from patients with prolonged diarrhea, Clin. Infect Dis., 18 (1994), 606-609.
19. P. L. Bhalla, Genetic engineering of wheat-current challenges and opportunities, Trends Biotechnol., 24 (2006), 305-311.
20. M. E. Bianchi, DAMPs, PAMPs and alarmins: all we need to know about danger, J. Leukoc Biol., 81 (2007), 1-5.
21. O. O. Bilukha and N. Rosenstein, Prevention and control of meningococcal disease, Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep., 54 (2005), 1-21.
22. R. Bock, Plastid biotechnology: prospects for herbicide and insect resistance, metabolic engineering and molecular farming, Curr. Opin. Biotechnol, 18 (2007), 100-106.
23. B. Bottazzi, A. Doni, C. Garlanda and A. Mantovani, An integrated view of humoral innate immunity: Pentraxins as a paradigm, Annu. Rev. Immunol., 28 (2010), 157-183.
24. D. J. Brayden, M. A. Jepson and A. W. Baird, Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting, Drug Discov. Today, 10 (2005), 1145-1157.
25. S. Brighenti and J. Andersson, Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection, Biochem. Biophys Res. Commun., 396 (2010), 50-57.
26. I. H. Brown, D. J. Alexander, P. Chakraverty, P. A. Harris and R. J. Manvell, Isolation of an influenza A virus of unusual subtype (H1N7) from pigs in England, and the subsequent experimental transmission from pig to pig, Vet. Microbiol., 39 (1994), 125-134.
27. I. H. Brown, P. A. Harris, J. W. McCauley and D. J. Alexander, Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype, J. Gen. Virol., 79 (Pt 12) (1998), 2947-2955.
28. A. Calmette, Preventive vaccination against tuberculosis with BCG, Proc. R. Soc. Med., 24 (1931), 1481-1490.
29. L. A. Campbell, C. C. Kuo and J. T. Grayston, Chlamydia pneumoniae and cardiovascular disease, Emerg. Infect Dis., 4 (1998), 571-579.
30. M. A. Campbell, H. A. Fitzgerald and P. C. Ronald, Engineering pathogen resistance in crop plants, Transgenic Res., 11 (2002), 599-613.
31. M. R. Castrucci, I. Donatelli, L. Sidoli, G. Barigazzi, Y. Kawaoka and R. G. Webster, Genetic reassortment between avian and human influenza A viruses in Italian pigs, Virology, 193 (1993), 503-506.
32. T. M. Chambers, V. S. Hinshaw, Y. Kawaoka, B. C. Easterday and R. G. Webster, Influenza viral infection of swine in the United States 1988-1989, Arch. Virol., 116 (1991), 261-265.
33. Z. Chen, A. Aspelund, G. Kemble and H. Jin, Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist), Virology, 345 (2006), 416-423.
34. K. M. Citron, BCG vaccination against tuberculosis: International perspectives, Bmj, 306 (1993), 222-223.
35. H. F. Clark, P. A. Offit, R. W. Ellis, J. J. Eiden, D. Krah, A. R. Shaw, M. Pichichero, J. J. Treanor, F. E. Borian, L. M. Bell and S. A. Plotkin, The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants, J. Infect Dis., 174 Suppl 1S (1996), 73-80.
36. J. Cohen and M. Enserink, Swine flu. after delays, WHO agrees: The 2009 pandemic has begun, Science, 324 (2009), 1496-1497.
37. G. A. Colditz, C. S. Berkey, F. Mosteller, T. F. Brewer, M. E. Wilson, E. Burdick and H. V. Fineberg, The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature, Pediatrics, 96 (1995), 29-35.
38. D. B. Collinge, H. J. Jorgensen, O. S. Lund and M. F. Lyngkjaer, Engineering pathogen resistance in crop plants: Current trends and future prospects, Annu. Rev. Phytopathol., 48 (2010), 269-291.
39. G. Corradin and G. del Giudice, "Novel Adjuvants for Vaccines," Current Medicinal Chemistry Anti-inflammatory and anti-allergy agents 4, 2005.
40. R. Curtiss, 3rd, W. Xin, Y. Li, W. Kong, S. Y. Wanda, B. Gunn and S. Wang, New technologies in using recombinant attenuated Salmonella vaccine vectors, Crit. Rev. Immunol., 30 (2010), 255-270.
41. G. De Becker, V. Moulin, B. Pajak, C. Bruck, M. Francotte, C. Thiriart, J. Urbain and M. Moser, The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells, Int. Immunol., 12 (2000), 807-815.
42. P. Delves, S. Martin, D. Burton and I. Roitt, "Essential Immunology," 11th ed. Wiley-Blackwell, 2006.
43. J. Diamond, "Guns, Gems and Steel: The Fates of Human Societies," 1st ed., W.W. Norton and Company, 1997.
44. R. Dommett, M. Zilbauer, J. T. George and M. Bajaj-Elliott, Innate immune defence in the human gastrointestinal tract, Mol. Immunol., 42 (2005), 903-912.
45. M. L. Duran-Reynals, "The Fever Bark Tree: The Pageant of Quinine," Doubleday, Garden City, 1946.
46. J. L. Ebersole, M. A. Taubman, D. J. Smith and J. M. Goodson, Gingival crevicular fluid antibody to oral microorganisms. I. Method of collection and analysis of antibody, J. Periodontal Res., 19 (1984), 124-132.
47. P. Ehrlich, Ueber moderne Chemotherapie. Vortrag gehalten in der X, Tagung der Deutschen Dermatologischen Gesellschaft. Akademische Verlagsgesellschaft m.b.H., Leipzig, 1908.
48. T. C. Elleman, A. A. Azad and C. W. Ward, Neuraminidase gene from the early Asian strain of human influenza virus, A/RI/5-/57 (H2N2), Nucleic Acids Res., 10 (1982), 7005-7015.
49. L. Epstein and S. Bassein, Patterns of pesticide use in California and the implications for strategies for reduction of pesticides, Annu. Rev. Phytopathol., 41 (2003), 351-375.
50. N. Ferry, M. G. Edwards, J. A. Gatehouse and A. M. Gatehouse, Plant-insect interactions: molecular approaches to insect resistance, Curr. Opin. Biotechnol., 15 (2004), 155-161.
51. R. H. Ffrench-Constant, P. J. Daborn and G. Le Goff, The genetics and genomics of insecticide resistance, Trends Genet., 20 (2004), 163-170.
52. A. Fleming, On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenza, Brit. J. Exp. Path., 10 (1929), 226-236.
53. J. E. Galen and M. M. Levine, Can a 'flawless' live vector vaccine strain be engineered? Trends Microbiol., 9 (2001), 372-376.
54. L. Garrett, "The Coming Plague: Newly Emerging Diseases in a World Out of Balance," 1st ed. Penguin, 1995.
55. R. J. Garten, C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, W. M. Sessions, X. Xu, E. Skepner, V. Deyde, M. Okomo-Adhiambo, L. Gubareva, J. Barnes, C. B. Smith, S. L. Emery, M. J. Hillman, P. Rivailler, J. Smagala, M. de Graaf, D. F. Burke, R. A. Fouchier, C. Pappas, C. M. Alpuche-Aranda, H. Lopez-Gatell, H. Olivera, I. Lopez, C. A. Myers, D. Faix, P. J. Blair, C. Yu, K. M. Keene, P. D. Dotson, Jr., D. Boxrud, A. R. Sambol, S. H. Abid, K. St George, T. Bannerman, A. L. Moore, D. J. Stringer, P. Blevins, G. J. Demmler-Harrison, M. Ginsberg, P. Kriner, S. Waterman, S. Smole, H. F. Guevara, E. A. Belongia, P. A. Clark, S. T. Beatrice, R. Donis, J. Katz, L. Finelli, C. B. Bridges, M. Shaw, D. B. Jernigan, T. M. Uyeki, D. J. Smith, A. I. Klimov and N. J. Cox, Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans, Science, 325 (2009), 197-201.
56. P. W. Gasper, A. M. Barnes, T. J. Quan, J. P. Benziger, L. G. Carter, M. L. Beard and G. O. Maupin, Plague (Yersinia pestis) in cats: Description of experimentally induced disease, J. Med. Entomol., 30 (1993), 20-26.
57. C. Gerdil, The annual production cycle for influenza vaccine, Vaccine, 21 (2003), 1776-1779.
58. R. Germanier and E. Furer, Isolation and characterization of galE mutant Ty21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine, J, Infect Dis., 131 (1975), 553-558.
59. M. J. Gething, J. Bye, J. Skehel and M. Waterfield, Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus, Nature, 287 (1980), 301-306.
60. A. Glenny, C. Pope, H. Waddington and U. Wallace, The antigenic value of toxoid precipitated by potassium alum, J. Pathol. Bacteriol., 29 (1926), 38-45.
61. J. Goedert, "Infectious Causes of Cancer: Targets for Intervention," Humana Press, New York, 2000.
62. R. Goldbach, E. Bucher and M. Prins. Resistance mechanisms to plant viruses: An overview, Virus Res., 92 (2003), 207-212.
63. R. Gomez-Lus, Evolution of bacterial resistance to antibiotics during the last three decades, Int. Microbiol, 1 (1998), 279-284.
64. E. C. Gotschlich, I. Goldschneider and M. S. Artenstein, Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers, J. Exp. Med., 129 (1969), 1367-1384.
65. I. M. Gould, The epidemiology of antibiotic resistance, Int. J. Antimicrob. Agents, 32 Suppl 1S (2008), 2-9.
66. R. K. Gupta, Aluminum compounds as vaccine adjuvants, Adv. Drug Deliv. Rev., 32 (1998), 155-172.
67. J. L. Hadler, K. Konty, K. H. McVeigh, A. Fine, D. Eisenhower, B. Kerker and L. Thorpe, Case fatality rates based on population estimates of influenza-like illness due to novel H1N1 influenza, New York City, May-June 2009. PLoS One, (2010), 5:e11677.
68. G. H. A. Hansen, Undersogelser angaende Spedalskedens Arsager (Investigations concerning the etiology of leprosy - translated and reprinted from the original 1874), Int. J. Lepr., 23 (1955), 307.
69. E. L. Hazen and R. Brown, Two antifungal agents produced by a soil actinomycete, Science, 112 (1950), 423.
70. P. Hedden, The genes of the Green Revolution, Trends Genet., 19 (2003), 5-9.
71. D. A. Henderson, The history of smallpox eradication, Henry E. Sigerist Suppl. Bull Hist. Med., (1980), 99-114.
72. S. E. Hensley, S. R. Das, A. L. Bailey, L. M. Schmidt, H. D. Hickman, A. Jayaraman, K. Viswanathan, R. Raman, R. Sasisekharan, J. R. Bennink and J. W. Yewdell, Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift, Science, 326 (2009), 734-736.
73. J. a. E. D. H. Hickling, A review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness In W. H. O. I. f. V. Research (ed.), Geneva, Switzerland, 2006.
74. V. S. Hinshaw, R. G. Webster, B. C. Easterday and W. J. Bean, Jr., Replication of avian influenza A viruses in mammals, Infect Immun., 34 (1981), 354-361.
75. V. S. Hinshaw, R. G. Webster, C. W. Naeve and B. R. Murphy, Altered tissue tropism of human-avian reassortant influenza viruses, Virology, 128 (1983.), 260-263.
76. J. Holmgren and C. Czerkinsky, Mucosal immunity and vaccines, Nat. Med., 11 (2005), S45-53.
77. K. M. Huster, C. Stemberger and D. H. Busch, Protective immunity towards intracellular pathogens, Curr. Opin. Immunol., 18 (2006), 458-464.
78. A. B. Hutchings, A. Helander, K. J. Silvey, K. Chandran, W. T. Lucas, M. L. Nibert and M. R. Neutra, Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches, J. Virol., 78 (2004), 947-957.
79. T. Ito and Y. Kawaoka, Host-range barrier of influenza A viruses, Vet. Microbiol., 74 (2000), 71-75.
80. B. Ivanoff, M. M. Levine and P. H. Lambert, Vaccination against typhoid fever: Present status, Bull World Health Organ., 72 (1994), 957-971.
81. B. L. Jacobs, J. O. Langland, K. V. Kibler, K. L. Denzler, S. D. White, S. A. Holechek, S. Wong, T. Huynh and C. R. Baskin, Vaccinia virus vaccines: Past, present and future, Antiviral Res., 84 (2009), 1-13.
82. C. A. Janeway, Jr. and R. Medzhitov, Innate immune recognition, Annu. Rev. Immunol., 20 (2002), 197-216.
83. S. W. Jarrett, Challenges to the successful introduction of biotechnologies in developing countries, Public Health Ethics, 1(2) (2008), 104-109.
84. M. K. Jenkins, A. Khoruts, E. Ingulli, D. L. Mueller, S. J. McSorley, R. L. Reinhardt, A. Itano and K. A. Pape, In vivo activation of antigen-specific CD4 T cells, Annu. Rev. Immunol., 19 (2001), 23-45.
85. E. Jenner, An inquiry into the causes and effects of the variol vaccine, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox, 1798.
86. H. Jin, B. Lu, H. Zhou, C. Ma, J. Zhao, C. F. Yang, G. Kemble and H. Greenberg, Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60, Virology, 306 (2003), 18-24.
87. D. Jones, H. J. Metzger, A. Schatz and S. A. Waksman, Control of gram-negative bacteria in experimental animals by streptomycin, Science, 100 (1944), 103-105.
88. R. N. Jones and M. A. Pfaller, Bacterial resistance: A worldwide problem, Diagn Microbiol. Infect Dis., 31 (1998), 379-388.
89. K. A. Jordan and C. A. Hunter, Regulation of CD8+ T cell responses to infection with parasitic protozoa, Exp. Parasitol., 126 (2010), 318-325.
90. J. Kaper, R. Rappuoli and M. Buckley, "Vaccine Development: Current Status and Future Needs," American Society for Microbiology, 2005.
91. B. G. a. L. P. Karlsson, Live viral vectors Semliki forest virus, Vaccine Protocols, 87 (2003), 69-81.
92. S. H. Kaufmann and U. E. Schaible, Antigen presentation and recognition in bacterial infections, Curr. Opin. Immunol., 17 (2005), 79-87.
93. B. F. Keele, E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn and G. M. Shaw, Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection, Proc. Natl. Acad. Sci. USA, 105 (2008), 7552-7557.
94. G. S. Khush, Green revolution: Preparing for the 21st century, Genome, 42 (1999), 646-655.
95. G. S. Khush, Green revolution: The way forward, Nat. Rev. Genet., 2 (2001), 815-822.
96. I. Kickbusch, World Health Organisation: Change and progress, Bmj, 310 (1995), 1518-1520.
97. R. Koch, The etiology of anthrax, based on the life history of Bacillus anthracis, Beitrage zur Biologie der Pflanzen, 2 (1877), 277-310.
98. R. Koch, The etiology of tuberculosis, Berliner Klinischen Wochenschrift, 15 (1882), 221-230.
99. C. N. Kotton and E. L. Hohmann, Enteric pathogens as vaccine vectors for foreign antigen delivery, Infect Immun., 72 (2004), 5535-5547.
100. P. A. Kozlowski, S. B. Williams, R. M. Lynch, T. P. Flanigan, R. R. Patterson, S. CuUvin and M. R. Neutra, Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: Influence of the menstrual cycle, J. Immunol., 169 (2002), 566-574.
101. G. Lauvau and N. Glaichenhaus, Mini-review: Presentation of pathogen-derived antigens in vivo, Eur. J. Immunol., 34 (2004), 913-920.
102. W. G. Laver, G. M. Air and R. G. Webster, Mechanism of antigenic drift in influenza virus. Amino acid sequence changes in an antigenically active region of Hong Kong (H3N2) influenza virus hemagglutinin, J. Mol. Biol., 145 (1981), 339-361.
103. J. Lederberg, Biological warfare: A global threat, Am. Sci., 59 (1971), 195-197.
104. J. R. Lees. and D. L. Farber, Generation, persistence and plasticity of CD4 T-cell memories, Immunology, 130 (2010), 463-470.
105. M. M. Levine, G. Dougan, J. B. Kaper, M. F. Good, M. A. Liu, G. J. Nabel, R. Rappuoli, J. P. Nataro (ed.), "New Generation Vaccines," 3rd ed. Informa Healthcare, 2004.
106. Y. Li, S. Wang, W. Xin, G. Scarpellini, Z. Shi, B. Gunn, K. L. Roland and R. Curtiss, III., A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines, Infect Immun., 76 (2008), 5238-5246.
107. P. Liljestrm, Overview: Virally based transient expression systems, Expert Opinion on Therapeutic Patents, 3 (1993), 375-402
108. J. M. Mann, W. J. Martone, J. M. Boyce, A. F. Kaufmann, A. M. Barnes and N. S. Weber, Endemic human plague in New Mexico: risk factors associated with infection, J. Infect Dis., 140 (1979), 397-401.
109. W. A. Marasco and J. Sui, The growth and potential of human antiviral monoclonal antibody therapeutics, Nat. Biotechnol., 25 (2007), 1421-1434.
110. D. Masopust, V. Vezys, E. J. Wherry and R. Ahmed, A brief history of CD8 T cells, Eur. J. Immunol., 37 Suppl 1S (2007), 103-110.
111. V. I. Mathan, Diarrhoeal diseases, British Medical Bulletin, 54 (1998), 407-419.
112. D. O. Matson, The pentavalent rotavirus vaccine, RotaTeq. Semin. Pediatr. Infect Dis., 17 (2006), 195-199.
113. C. McEvedy, The bubonic plague, Sci. Am., 258 (1988), 118-123.
114. K. K. McKinstry, T. M. Strutt and S. L. Swain, The potential of CD4 T-cell memory, Immunology, 130 (2010), 1-9.
115. W. H. McNeill, "Plagues and Peoples," 1st ed. Doubleday/Anchor, 1976.
116. R. L. Metcalf, Mode of action of insecticide synergists, Annu. Rev. Entomol., 12 (1967), 229-256.
117. E. Metchnikoff, "Immunity in Infective Diseases," Cambridge Univ. Press, Translated by F. G. Binnie, Cambridge, Reprinted 1905.
118. J. D. Miller, R. G. van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, S. Germon, C. Del Rio, M. J. Mulligan, S. I. Staprans, J. D. Altman, M. B. Feinberg and R. Ahmed, Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines, Immunity, 28 (2008), 710-722.
119. R. Mittler and E. Blumwald, Genetic engineering for modern agriculture: challenges and perspectives, Annu. Rev. Plant Biol., 61 (2010), 443-462.
120. F. R. Mooi, I. H. van Loo, M. van Gent, Q. He, M. J. Bart, K. J. Heuvelman, S. C. de Greeff, D. Diavatopoulos, P. Teunis, N. Nagelkerke and J. Mertsola, Bordetella pertussis strains with increased toxin production associated with pertussis resurgence, Emerg. Infect Dis., 15 (2009), 1206-1213.
121. P. Morgane, M. Miller, T. Kemper, W. Stern, W. Forbes, R. Hall, J. Bronzino, J. Kissane, E. Hawrylewicz and O. Resnick, The effects of protein malnutrition on the developing central nervous system in the rat, Neurosci. and Biobehav. Rev., 2 (1978), 137-230.
122. F. Mourgues, M. N. Brisset and E. Chevreau, Strategies to improve plant resistance to bacterial diseases through genetic engineering, Trends Biotechnol., 16 (1998), 203-210.
123. C. A. Muller, I. B. Autenrieth and A. Peschel, Innate defenses of the intestinal epithelial barrier, Cell Mol. Life Sci., 62 (2005), 1297-1307.
124. W. Muraskin, "The Politics of International Health," State University of New York, Albany, 1998.
125. K. P. Murphy, P. Travers, M. Walport and C. Janeway, "Janeway's Immunobiology," 7th ed. Garland Science, New York, 2008.
126. C. J. Murray, A. D. Lopez and D. T. Jamison, The global burden of disease in 1990: Summary results, sensitivity analysis and future directions, Bull World Health Organ., 72 (1994), 495-509.
127. G. Neumann, H. Chen, G. F. Gao, Y. Shu and Y. Kawaoka, H5N1 influenza viruses: Outbreaks and biological properties, Cell Res., 20 (2009), 51-61.
128. G. Neumann, T. Horimoto and Y. Kawaoka, Reverse genetics of influenza viruses-applications in research and vaccine design, In M. M. Klenk H-D, Stech J. (ed.), "Avian Influenza (Monographs in Virology)" vol. 27, Basel, (2008), 116-133.
129. M. R. Neutra and P. A. Kozlowski, Mucosal vaccines: The promise and the challenge, Nat. Rev. Immunol., 6 (2006), 148-158.
130. M. O'Ryan, Rotarix (RIX4414): an oral human rotavirus vaccine, Expert Rev. Vaccines, 6 (2007), 11-19.
131. M. B. Oldstone, Molecular mimicry, microbial infection, and autoimmune disease: Evolution of the concept, Curr. Top Microbiol. Immunol., 296 (2005), 1-17.
132. B. Olsen, V. J. Munster, A. Wallensten, J. Waldenstrom, A. D. Osterhaus and R. A. Fouchier, Global patterns of influenza a virus in wild birds, Science, 312 (2006), 384-388.
133. E. Paoletti, M. E. Perkus and A. Piccini, Live recombinant vaccines using genetically engineered vaccinia virus, Antiviral Res., Suppl 1 (1985), 301-307.
134. P. Paradiso, Essential criteria for evaluation of pneumococcal conjugate vaccine candidates, Vaccine, 27 Suppl 3C (2009), 15-18.
135. P. Parham and C. Janeway, "The Immune System," 3rd ed. Garland Science, London ; New York, 2009.
136. J. Partridge and M. P. Kieny, Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets, Vaccine, 28 (2010), 4709-4712.
137. L. Pasteur, De l'attenuation du virus du cholera des poules, Comptes rendus de l'Academie des sciences, 91 (1880), 673-680.
138. M. L. Pasteur and M. M. Chamberland, De l'attenuation des virus et de leur retour a la virulence, C. R. Acad. Sci. Agric. Bulg., 92 (1881), 429-435.
139. P. A. Patriarca, P. F. Wright and T. J. John, Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review, Rev. Infect Dis., 13 (1991), 926-939.
140. H. Peltola, H. Kayhty, M. Virtanen and P. H. Makela, Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine, N. Engl. J. Med., 310 (1984), 1561-1566.
141. S. Pelzer, A. Vente and A. Bechthold, Novel natural compounds obtained by genome-based screening and genetic engineering, Curr. Opin. Drug Discov. Devel., 8 (2005), 228-238.
142. J. Peng, D. E. Richards, N. M. Hartley, G. P. Murphy, K. M. Devos, J. E. Flintham, J. Beales, L. J. Fish, A. J. Worland, F. Pelica, D. Sudhakar, P. Christou, J. W. Snape, M. D. Gale and N. P. Harberd, 'Green revolution' genes encode mutant gibberellin response modulators, Nature, 400 (1999), 256-261.
143. M. E. Perkus, A. Piccini, B. R. Lipinskas and E. Paoletti, Recombinant vaccinia virus: immunization against multiple pathogens, Science, 229 (1985), 981-984.
144. D. H. Persing, R. N. Coler, M. J. Lacy, D. A. Johnson, J. R. Baldridge, R. M. Hershberg and S. G. Reed, Taking toll: Lipid A mimetics as adjuvants and immunomodulators, Trends Microbiol., 10:S (2002), 32-37.
145. D. Pimentel, Green revolution agriculture and chemical hazards, Sci. Total Environ., 188 Suppl 1:S (1996), 86-98.
146. F. W. Plapp, Biochemical genetics of insecticide resistance, Annu. Rev. Entomol., 21 (1976), 179-197.
147. S. A. Plotkin, Correlates of protection induced by vaccination, Clin. Vaccine Immunol., 17 (2010), 1055-1065.
148. S. A. Plotkin, Vaccines: the fourth century, Clin. Vaccine Immunol., 16 (2009), 1709-1719.
149. J. D. Poland and A. M. Barnes, "1979 Plague," In J. H. Steele (ed.), CRC handbook series in zoonoses, vol. I. CRC Press Inc., Boca Raton, FL, 515-559
150. J. D. T. J. Q. Poland and A. M. Barnes, "1994. Plague," In G. W. Beran (ed.), Handbook of zoonoses, 2nd ed, vol. I. CRC Press, Inc., Ann Arbor, MI., 93-112.
151. R. Pollitzer, Plague, Geneva, Switzerland: WHO Monograph Series, 22 (1954), 1698.
152. P. Prusiner and M. Sundaralingam, A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties, Nat. New Biol., 244 (1973), 116-118.
153. T. D. Querec, R. S. Akondy, E. K. Lee, W. Cao, H. I. Nakaya, D. Teuwen, A. Pirani, K. Gernert, J. Deng, B. Marzolf, K. Kennedy, H. Wu, S. Bennouna, H. Oluoch, J. Miller, R. Z. Vencio, M. Mulligan, A. Aderem, R. Ahmed and B. Pulendran, Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans, Nat. Immunol., 10 (2009), 116-125.
154. M. C. Raviglione, D. E. Snider, Jr. and A. Kochi, Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic, Jama, 273 (1995), 220-226.
155. I. Rudan, S. El Arifeen, R. E. Black and H. Campbell, Childhood pneumonia and diarrhoea: Setting our priorities right, Lancet Infect Dis., 7 (2007), 56-61.
156. A. B. Sabin, Oral, live poliovirus vaccine for elimination of poliomyelitis, Arch. Intern. Med., 106 (1960), 5-9.
157. A. B. Sabin, M. Ramos-Alvarez, J. Alvarez-Amezqita, W. Pelon, R. H. Michaels, I. Spigland, M. Koch, J. Barnes and J. Rhim, Effects of rapid mass immunization of a population with live, oral poliovirus vaccine under conditions of massive enteric infection with other viruses, Trans. Assoc. Am. Physicians, 73 (1960), 128-139.
158. J. F. Salazar-Gonzalez, M. G. Salazar, B. F. Keele, G. H. Learn, E. E. Giorgi, H. Li, J. M. Decker, S. Wang, J. Baalwa, M. H. Kraus, N. F. Parrish, K. S. Shaw, M. B. Guffey, K. J. Bar, K. L. Davis, C. Ochsenbauer-Jambor, J. C. Kappes, M. S. Saag, M. S. Cohen, J. Mulenga, C. A. Derdeyn, S. Allen, E. Hunter, M. Markowitz, P. Hraber, A. S. Perelson, T. Bhattacharya, B. F. Haynes, B. T. Korber, B. H. Hahn and G. M. Shaw, Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection, J. Exp. Med., 206 (2009), 1273-1289.
159. G. Sandmann, S. Romer and P. D. Fraser, Understanding carotenoid metabolism as a necessity for genetic engineering of crop plants, Metab. Eng., 8 (2006), 291-302.
160. J. Sanford, V. Mitchell and N. Philipose, "The Children's Vaccine Initiative: Achieving the Vision," National Academy Press, Washington, DC, 1993.
161. N. Santos and Y. Hoshino, Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine, Rev. Med. Virol., 15 (2005), 29-56.
162. S. Scheurer and S. Sonnewald, Genetic engineering of plant food with reduced allergenicity, Front Biosci., 14 (2009), 59-71.
163. G. C. Schild, J. S. Oxford, W. R. Dowdle, M. Coleman, M. S. Pereira and P. Chakraverty, Antigenic variation in current influenza A viruses: Evidence for a high frequency of antigenic 'drift' for the Hong Kong virus, Bull World Health Organ., 51 (1974), 1-11.
164. U. Schultz, W. M. Fitch, S. Ludwig, J. Mandler and C. Scholtissek, Evolution of pig influenza viruses, Virology, 183 (1991), 61-73.
165. W. S. Shalaby, Development of oral vaccines to stimulate mucosal and systemic immunity: Barriers and novel strategies, Clin. Immunol. Immunopathol., 74 (1995), 127-134.
166. I. W. Sherman, "Twelve Diseases That Changed Our World," 1st ed. ASM Press, 2007.
167. C. A. Siegrist, The challenges of vaccine responses in early life: Selected examples, J. Comp. Pathol., 137 Suppl 1:S (2007), 4-9.
168. C. A. Siegrist, Neonatal and early life vaccinology, Vaccine, 19 (2001), 3331-3346.
169. P. Slack, The black death past and present, II: Some historical problems, Trans. R. Soc. Trop. Med. Hyg., 83 (1989), 461-463.
170. G. J. Smith, D. Vijaykrishna, J. Bahl, S. J. Lycett, M. Worobey, O. G. Pybus, S. K. Ma, C. L. Cheung, J. Raghwani, S. Bhatt, J. S. Peiris, Y. Guan and A. Rambaut, Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic, Nature, 459 (2009), 1122-1125.
171. G. L. Smith and B. Moss, Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA, Gene, 25 (1983), 21-28.
172. L. Somerville, The metabolism of fungicides, Xenobiotica, 16 (1986), 1017-1030.
173. J. L. Soosaar, T. M. Burch-Smith and S. P. Dinesh-Kumar, Mechanisms of plant resistance to viruses, Nat. Rev. Microbiol., 3 (2005), 789-798.
174. A. R. Spickler and J. A. Roth, Adjuvants in veterinary vaccines: modes of action and adverse effects, J. Vet. Intern. Med., 17 (2003), 273-281.
175. S. Stefani and P. E. Varaldo, Epidemiology of methicillin-resistant staphylococci in Europe, Clin. Microbiol. Infect., 9 (2003), 1179-1186.
176. A. J. Stewart and P. M. Devlin, The history of the smallpox vaccine, J. Infect., 52 (2006), 329-334.
177. R. A. Strugnell and O. L. Wijburg, The role of secretory antibodies in infection immunity, Nat. Rev. Microbiol., 8 (2010), 656-667.
178. Y. Suzuki, T. Ito, T. Suzuki, R. E. Holland, Jr., T. M. Chambers, M. Kiso, H. Ishida and Y. Kawaoka, Sialic acid species as a determinant of the host range of influenza A viruses, J. Virol., 74 (2000), 11825-11831.
179. K. Takeda and S. Akira, TLR signaling pathways, Semin. Immunol., 16 (2004), 3-9.
180. J. K. Taubenberger and D. M. Morens, 1918 Influenza: The mother of all pandemics, Emerg. Infect. Dis., 12 (2006), 15-22.
181. W. D. Tigertt, Plague, In: Evans AS, Brachman PS, eds. "Bacterial Infections of Humans," New York, NY: Plenum; 1991, 513-523.
182. J. Tu, H. Zhou, T. Jiang, C. Li, A. Zhang, X. Guo, W. Zou, H. Chen and M. Jin, Isolation and molecular characterization of equine H3N8 influenza viruses from pigs in China, Arch. Virol., 154 (2009), 887-890.
183. M. V. Tullius, G. Harth, S. Maslesa-Galic, B. J. Dillon and M. A. Horwitz, A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG, Infect. Immun., 76 (2008), 5200-5214.
184. P. Valenti and G. Antonini, Lactoferrin: An important host defence against microbial and viral attack, Cell Mol. Life Sci., 62 (1980), 2576-2587.
185. F. W. van Ginkel, H. H. Nguyen and J. R. McGhee, Vaccines for mucosal immunity to combat emerging infectious diseases, Emerg. Infect. Dis., 6 (1980), 123-132.
186. R. E. Vance, R. R. Isberg and D. A. Portnoy, Patterns of pathogenesis: Discrimination of pathogenic and nonpathogenic microbes by the innate immune system, Cell Host Microbe, 6 (1980), 10-21.
187. M. Verhoeyen, R. Fang, W. M. Jou, R. Devos, D. Huylebroeck, E. Saman and W. Fiers, Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75, Nature, 286 (1980), 771-776.
188. P. P. Ward and O. M. Conneely, Lactoferrin: Role in iron homeostasis and host defense against microbial infection, Biometals, 17 (2004), 203-208.
189. P. P. Ward, S. Uribe-Luna and O. M. Conneely, Lactoferrin and host defense, Biochem. Cell Bio., 80 (2002), 95-102.
190. S. Watts, "Epidemics in History: Disease, Power, and Imperialism," 1st ed. Yale University Press, London, 1997.
191. R. G. Webster, W. J. Bean, O. T. Gorman, T. M. Chambers and Y. Kawaoka, Evolution and ecology of Influenza A viruses, Microbiol. Rev., 56 (1992), 152-179.
192. A. Weintraub, Immunology of bacterial polysaccharide antigens, Carbohydr. Res., 338 (2003), 2539-2547.
193. WHO, "The Global Burden of Disease: 2004 Update," 2008.
194. B. N. Wilkie, J. R. Duncan and A. J. Winter, The origin, class and specificity of immunoglobulins in bovine cervico-vaginal mucus: Variation with parenteral immunization and local infection with Vibrio fetus, J. Reprod. Fertil., 31 (1972), 359-365.
195. W. Witte, C. Cuny, I. Klare, U. Nubel, B. Strommenger and G. Werner, Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens, Int. J. Med. Microbiol., 298 (2008), 365-377.
196. T. E. Woodward, J. E. Smadel and et al., Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever, Ann. Intern. Med., 29 (1948), 131-134.
197. M. Zanetti, P. Castiglioni and E. Ingulli, Principles of memory CD8 T-cells generation in relation to protective immunity, Adv. Exp. Med. Biol., 684 (2010), 108-125.